Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting
Abstract B cell maturation antigen (BCMA)-targeted immunotherapy has shown unprecedented results in the treatment of relapsed or refractory (R/R) multiple myeloma (MM). However, disease progression remains an issue attributed to variable BCMA expression, BCMA downregulation, and heterogeneity of tum...
| Published in: | Journal of Hematology & Oncology |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-06-01
|
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-023-01461-1 |